Montag A & Associates Inc. Sells 644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Montag A & Associates Inc. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 82.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139 shares of the biopharmaceutical company’s stock after selling 644 shares during the quarter. Montag A & Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $99,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $49,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $673.60 on Tuesday. The firm has a 50 day moving average of $706.92 and a 200-day moving average of $894.87. The company has a market cap of $74.02 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $11.86 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%.

Analysts Set New Price Targets

Several brokerages have weighed in on REGN. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Robert W. Baird reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 5th. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.